Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/04c1ac47-688d-4400-a389-c61c1fd17b1a/

CUV

Clinuvel Pharmaceuticals Limited
Chart
10.27 AUD
Latest Week 2026-07-10
HealthcareBiotechnologySMALL
Snapshot 2026-07-12 · 0.7w · Fresh
0.86
OS Score
93.0%
Value
98.0%
Quality
14.0%
Momentum
3/9
F-Score
0.955
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
3 of 23 passing
★
OS Composite
OS 0.860
↗
Trending Value
✗
◆
Quality × Value
QV 0.955
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
19.4%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
93.0%ile
P/E
14.3×
P/S
5.5×
P/B
2.2×
E/P
0.1554
FCF Yield
0.139
EBITDA/EV
0.194
SH Yield
0.005
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
14.00000000
/100 — 1=cheapest
VC2 (Trending Value)
16.00000000
/100
VC3 (Buyback)
17.00000000
/100
FCF yield of 13.9% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
98.0%ile
ROE
0.150
ROA
0.133
Net Margin
0.381
Op Margin
0.481
GPA
0.291
Current
9.66
F-Score
3/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.078
Earn Growth
0.014
5yr Consist
No
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
14.0%ile
6M Return
-18.8%
12M Return
-2.5%
12-1 Mom
-14.9%
Risk-Adj
-0.35
Vol 252d
43.1%
Vol 60d
85.1%
↑ Expanding
Max DD 12M
-32.3%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -15% signals a downtrend — price is moving against you. Near-term vol (85%) is expanding vs long-term (43%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.86
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 145 peers
Sector Value %ile
97.3%
Sector Quality %ile
97.9%
P/E z-score
-0.48
P/B z-score
-0.42
Sector Avg OS
39.7%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
VLS Vita Life Sciences Limited 98.0% 94.0% 97.0% 88.0%
SDI SDI Limited 96.0% 86.0% 89.0% 95.0%
ALC Alcidion Group Limited 93.0% 81.0% 79.0% 81.0%
RGT Argent BioPharma Limited 93.0% 81.0% 80.0% 81.0%
AGN Argenica Therapeutics Limited 93.0% 82.0% 80.0% 81.0%
BB1 BLINKLAB FPO [BB1] 93.0% 81.0% 80.0% 81.0%
ENP Entropy Neurodynamics Limited 92.0% 80.0% 78.0% 80.0%
ECS ECS Botanics Holdings Ltd 92.0% 80.0% 79.0% 80.0%
Factor Interactions
Value + Quality Intersection
Top-tier on both cheapness (93th) and quality (98th) — the O'Shaughnessy sweet spot, historically the strongest long-term combination.
Falling Knife
Weak momentum (14th) despite looking cheap (93th value). Wait for momentum to stabilise.
Volatility Expanding
60-day vol (85%) significantly exceeds 252-day (43%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
A
76.7% avg (7 factors)
Quality
A
78.0% avg (6 factors)
Momentum
F
18.6% avg (4 factors)
Risk
D
44.9% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns. Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends6 snapshots
Factor Persistence6 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.860—6—
Value %ile0.930—6—
Quality %ile0.980—6—
Momentum %ile0.140—6—
F-Score3.000—6—
Confidence0.470—0—
Volatility0.431—6—
Value Lens2021-07-13 → 2026-07-12
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
14.32
Earnings Yield (E/P)
0.1554
Price / Sales
5.45
Price / Book
2.15
FCF Yield
13.9%
EBITDA / EV
19.4%
Sales Yield (1/P·S)
0.3228
Shareholder Yield
Div + net buyback / mktcap
0.5%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
15.0%
Return on Assets
13.3%
Net Margin
38.1%
Operating Margin
48.1%
Gross Profit / Assets
Novy-Marx GPA
29.1%
Current Ratio
9.66
External Financing
Net issuance — lower=better
0.002
MomentumPrice trend strength over different horizons
6M Return
-18.8%
12M Return
-2.5%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-14.9%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.35
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
1.4%
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
3
Dividend Yield
0.5%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
14
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
16
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
17
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity